Hypertrigly ceridemia and Its pharmacologic treatment among US adults

Archives of Internal Medicine

Volumn 169, Issue 6, 2009, Pages 572-578

  Ford, Earl S ^a,b   Li, Chaoyang ^a   Zhao, Guixiang ^a   Pearson, William S ^a   Mokdad, Ali H ^a  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^b Centers for Disease Con trol and Prevention   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; EZETIMIBE; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; ANTILIPEMIC AGENT;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; DISEASE SURVEILLANCE; DRUG EFFICACY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; OBESITY; PREVALENCE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES; MIDDLE AGED; NUTRITION;

ADULT; ANTILIPEMIC AGENTS; FEMALE; GEMFIBROZIL; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; MIDDLE AGED; NIACIN; NUTRITION SURVEYS; PREVALENCE; PROCETOFEN; UNITED STATES; YOUNG ADULT;

EID: 63849198178     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2008.599     Document Type: Article

References (28)

1. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a metaanalysis of population-based prospective studies. J Cardiovasc Risk. 1996; 3(2):213-219.
2. Patel A, Barzi F, Jamrozik K, et al. Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation. 2004;110(17):2678- 2686.
3. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007;115(4):450-458.
4. Tirosh A, Rudich A, Shochat T, et al. Changes in triglyceride levels and risk for coronary heart disease in young men. Ann Intern Med. 2007;147(6):377-385.
5. Carroll MD, Lacher DA, Sorlie PD, et al. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA. 2005;294(14):1773-1781.
6. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey 2007. http://www.cdc.gov/nchs/about/major/nhanes/datalink. htm. Accessed January 7, 2008.
7. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421.
8. Pate RR, Pratt M, Blair SN, et al. Physical activity and public health: a recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA. 1995;273(5):402-407.
9. Studer M, Briel M, Leimenstoll B, Glass TR, Bucher HC. Effect of different anti- lipidemic agents and diets on mortality: a systematic review. Arch Intern Med. 2005;165(7):725-730.
10. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001;357(9260):905-910.
11. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849-1861.
12. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987; 317(20):1237-1245.
13. Rubins HB, Robins SJ, Collins D, et al; Veterans Affairs High-Density Lipopro- tein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-densityli- poprotein cholesterol. N Engl J Med. 1999;341(6):410-418.
14. Eberly LE, Stamler J, Neaton JD. Relation of triglyceride levels, fasting and non-fasting, to fatal and nonfatal coronary heart disease. Arch Intern Med. 2003; 163(9):1077-1083.
15. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglyc-eridesand risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298(3):299-308.
16. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007;298(3):309-316.
17. Krauss RM, Burkman RT Jr. The metabolic impact of oral contraceptives. Am J Obstet Gynecol. 1992;167(4, pt 2):1177-1184.
18. Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil Steril. 2001;75(5):898-915.
19. Frerichs RR, Srinivasan SR, Webber LS, Berenson GR. Serum cholesterol and triglyceride levels in 3,446 children from a biracial community: the Bogalusa Heart Study. Circulation. 1976;54(2):302-309.
20. Tyroler HA, Glueck CJ, Christensen B, Kwiterovich PO Jr. Plasma high-density lipoprotein cholesterol comparisons in black and white populations: the Lipid Research Clinics Program Prevalence Study. Circulation. 1980;62(4, pt 2): IV99-IV107.
21. Heiss G, Schonfeld G, Johnson JL, Heyden S, Hames CG, Tyroler HA. Black-white differences in plasma levels of apolipoproteins: the Evans County Heart Study. Am Heart J. 1984;108(3, pt 2):807-814.
22. Donahue RP, Jacobs DR Jr, Sidney S, Wagenknecht LE, Albers JJ, Hulley SB. Distribution of lipoproteins and apolipoproteins in young adults: the CARDIA Study. Arteriosclerosis. 1989;9(5):656-664.
23. Brown SA, Hutchinson R, Morrisett J, et al. Plasma lipid, lipoprotein choles-terol, and apoprotein distributions in selected US communities: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb. 1993;13(8):1139-1158.
24. Vega GL, Adams-Huet B, Peshock R, Willett D, Shah B, Grundy SM. Influence of body fat content and distribution on variation in metabolic risk. J Clin Endocrinol Metab. 2006;91(11):4459-4466.
25. Holvoet P, Jenny NS, Schreiner PJ, Tracy RP, Jacobs DR. The relationship between oxidized LDL and other cardiovascular risk factors and subclinical CVD in different ethnic groups: the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2007;194(1):245-252.
26. Friday KE, Srinivasan SR, Elkasabany A, et al. Black-white differences in postprandial triglyceride response and postheparin lipoprotein lipase and hepatic triglyceride lipase among young men. Metabolism. 1999;48(6):749-754.
27. Després JP, Couillard C, Gagnon J, et al. Race, visceral adipose tissue, plasma lipids, and lipoprotein lipase activity in men and women: the Health, Risk Factors, Exercise Training, and Genetics (HERITAGE) family study. ArteriosclerThromb Vasc Biol. 2000;20(8):1932-1938.
28. Martins D, Tareen N, Ogedegbe G, Pan D, Norris K. The relative risk of cardiovascular death among racial and ethnic minorities with metabolic syndrome: data from the NHANES-II mortality follow-up. J Natl Med Assoc. 2008;100(5):565-571.